Published in J Urol on August 29, 2015
Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. Prostate Cancer Prostatic Dis (2016) 0.76
Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers. Prostate Int (2016) 0.76
Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis (2016) 0.75
MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS One (2016) 0.75
A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment. Prostate Cancer Prostatic Dis (2016) 0.75
The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. Urology (2017) 0.75
Prostate cancer: Caveat Emptor - long-term outcomes in the Göteborg active surveillance cohort. Nat Rev Urol (2016) 0.75
Active Surveillance for Intermediate Risk Prostate Cancer. Curr Urol Rep (2017) 0.75
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2012) 15.83
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol (2005) 12.31
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (1998) 8.33
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol (1974) 5.26
Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol (2014) 5.01
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Eur Urol (2014) 1.80
Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer (2013) 1.75
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol (2011) 1.33
Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32
Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. J Urol (2011) 1.19
Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. Cancer Epidemiol Biomarkers Prev (2016) 1.29
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res (2014) 1.27
Plasma choline metabolites and colorectal cancer risk in the Women's Health Initiative Observational Study. Cancer Res (2014) 0.98
Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. Am J Prev Med (2016) 0.77
American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy Update. J Urol (2017) 0.75
Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Development of a 90-minute integrated non-invasive urinary assay for bladder cancer detection. J Urol (2017) 0.75
Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol (2016) 0.75
Optimizing active surveillance strategies to balance the competing goals of early detection of grade progression and minimizing harm from biopsies. Cancer (2017) 0.75
AUA White Paper on Nonneurogenic Chronic Urinary Retention: Consensus Definition, Treatment Algorithm, and Outcome End Points. J Urol (2017) 0.75
Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clin Cancer Res (2017) 0.75